Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer by Vanna Chiarion-Sileni et al.
Cancer Chemother Pharmacol (2009) 63:1111–1119
DOI 10.1007/s00280-008-0834-3
ORIGINAL ARTICLE
Multi-center phase II trial of chemo-radiotherapy 
with 5-Xuorouracil, leucovorin and oxaliplatin in locally 
advanced esophageal cancer
Vanna Chiarion-Sileni · Roberto Innocente · RaVaele Cavina · Alberto Ruol · 
Luigi Corti · Jacopo Pigozzo · Paola Del Bianco · Uberto Fumagalli · 
Armando Santoro · Ermanno Ancona 
Received: 18 June 2008 / Accepted: 8 September 2008 / Published online: 30 September 2008
©  The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract
Purpose The aim of this study was to evaluate the activity
and safety of oxaliplatin/5-Xuorouracil-based chemo-radio-
therapy in patients with not radically resectable locally
advanced esophageal cancer.
Methods Fifty-nine patients with adeno or squamous-cell
carcinoma received oxaliplatin (60 mg/m2), and leucovorin
(20 mg/m2 on days 1,8,15,29,36,43,50,57) followed by
continuous infusion Xuorouracil (200 mg/m2 per day on
days 1–22 and 29–64) with radiotherapy (1.8 Gy daily frac-
tions to a total dose of 45 Gy, from days 29 to 64). When
feasible, surgery was scheduled 6–8 weeks after chemo-
radiotherapy completion. The primary endpoint was 1-year
progression-free survival.
Results Forty (68%) patients completed treatment without
modiWcations. An objective clinical response was seen in
35 patients (59%). Esophagectomy was possible in 33
patients and a complete resection (R0) was achieved in 26
(79%) with 6 pathologic complete responses (pCR) and 3
near pCR.
At a median follow-up of 39.7 months for the surviving
patients, the median progression-free and overall survivals
were 11 months (95% CI 6.5–14) and 18.5 months (95% CI
13–29). The 1-year progression-free and overall survivals
were 47.5% (95% CI 34–59.5%) and 63% (95% CI 49–
74%). Major toxicities were esophagitis (20% G3 and 5%
G4) and diarrhea (8.5% G3 and 8.5% G4). Hematological
toxicity (7% G3 and 3% G4) was less common; severe
neurotoxicity (3% G3) was infrequent.
Conclusions Concurrent oxaliplatin, leucovorin, Xuoro-
uracil and radiotherapy followed or not by esophagectomy
has a tolerable toxicity and promising activity in locally
advanced esophageal cancer.
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Esophageal carcinoma is a highly aggressive neoplasm with
long-term survival rates below 20%. The lethality of this
disease is a consequence of advanced disease stage at diag-
nosis combined with dysphagia, weight loss and co-morbid
conditions, related to alcohol and tobacco abuse [13].
Surgery is still considered to be the standard treatment
for patients who are medically Wt and in whom a complete
resection can be achieved [24], while chemo-radiotherapy
is the standard treatment for patients with locally advanced
disease or medically unWt for surgery [12, 21, 29]. Never-
theless, neither approach is particularly eVective with loco-
regional failure and distant metastasis, both common after
either treatment. More recently squamous cell cancer and
adenocarcinoma of the esophagus have been recognized as
two distinct entities with diVerences in pathogenesis, epide-
miology, tumor biology and prognosis [35]. A recent meta-
analysis evidenced a signiWcant survival beneWt with preop-
erative chemo-radiotherapy in both histological tumor
types [18], while preoperative chemotherapy was eVective
to a lesser extent only in adenocarcinoma. To date, random-
ized trials on squamous cell carcinoma, have not demon-
strated any beneWt on survival. The signiWcant
postoperative mortality might have aVected the possible
therapeutic beneWt; however, surgical resection had a sub-
stantial improvement in local control and decreased the
need for stent placement [6, 37].
Four cycles of Xuorouracil/cisplatin, with radiotherapy
(50.4 Gy/5 weeks), is the standard regimen for locally
advanced patients, but relevant toxicity prevented the full
administration of chemotherapy in 46% of patients and
caused acute life-threatening toxic eVects in 20% [12, 21].
Moreover, when cisplatin-based chemo-radiotherapy was
followed by surgery, postoperative mortality increased in
some studies to 12% [38].
Oxaliplatin (trans-l-1,2-diaminocyclohexane oxaliplati-
num), a novel anti-neoplastic platinum analog, has been
safely and eVectively combined with Xuorouracil/leucovo-
rin, in the treatment of colon and rectal cancer [15, 16]. In
advanced esophagogastric cancer, oxaliplatin, combined
with Xuorouracil and epirubicin or epirubicin and capecita-
bine, in a phase III study, was as eVective as the cisplatin
combination and associated with less neutropenia, renal
toxicity and alopecia [14]; and in combination with Xuoro-
uracil and leucovorin was more eVective than a cisplatin-
based combination in patients older than 65 years [2].
Pre-clinical studies have also shown that oxaliplatin is a
potent radio-sensitizing agent [7].
The eYcacy and safety of combining oxaliplatin/Xuoro-
uracil and radiation were Wrst established in phase I and II
studies in rectal cancer [9, 17], and esophageal cancer [25].
In advanced (T3 and T4) esophageal cancer, a complete
clearance of tumor cells is more diYcult to obtain [34]. A
weekly schedule, which should optimize the inhibition of
sub-lethal radiation-induced DNA damage repair [4, 11],
might increase the pathological complete response (pCR)
rate through greater tumor shrinkage. In a phase I study, our
group demonstrated that oxaliplatin, given weekly in com-
bination with full-dose infusional FU and RT, is an active
regimen in advanced rectal cancer [4]. The favorable toxic-
ity proWle of this regimen, reXected in the high treatment
compliance, the full dose of radiation delivered and the low
surgical morbidity, prompted us to test this combination in
locally advanced esophageal cancer (LAEC) patients.
On the basis of these data, we planned this study to
assess the eYcacy and safety of oxaliplatin/leucovorin/Xuo-
rouracil (FLOX) and radiotherapy in a multi-institutional
phase II trial, in patients with LAEC.
The primary end-point of this study was to evaluate the
eYcacy of this combination in both histologies. Dealing
with LAEC patients where the evaluation of clinical
response is diYcult and the pathological response is valu-
able only in resected patients, we chose the 1-year progres-
sion-free survival (PFS) as a measure of eYcacy. PFS is
less controversial than the response rate and can be applied
to all patients, even those who do not become operable,
decline surgery, or die before evaluation.
Secondary endpoints included overall survival (OS),
toxicity, response, pCR and complete resection rates, surgi-
cal morbidity and mortality.
Patients and methods
Patients aged less than 75 years, with an ECOG perfor-
mance status ·2, a histologically conWrmed diagnosis of
LAEC, a squamous cell carcinoma or adenocarcinoma, and
the American Joint Committee on Cancer [20] Stages IIB–
IVA, not radically resectable, were eligible. The criteria for
unresectability were deWned as follows: adherence to the
aorta of more then 90°; invasion of the tracheo-bronchial
tree, azygos vein, recurrent nerve; M1a nodal metastases,
cervical esophagus involvement. Patients with T lesions
less than T4 in the presence of extensive nodal involvement
were also included. Criteria for non-operability were cir-
rhosis (any stage) associated with portal vein hypertension,
respiratory failure, and heart failure (New York Heart
Association classes III–IV). Further requirements for eligi-
bility included an initial absolute neutrophil
count ¸ 2 £ 109/l; platelet count ¸ 150 £ 109/l; adequate
hepatic (AST and ALT <two times normal, bilirubin
level < 20 mmol/l) and renal (serum creatinine
level < 150 mol/l) function. Patients were excluded due to
the following: ¸grade 2 neuropathy, tracheal-esophageal
Wstula, severe co-morbid conditions, active infections.123
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Before entering the study, all patients were evaluated by
a multidisciplinary team, which included a medical
oncologist, a radiotherapist, a surgeon and a gastroenter-
ologist, and were required to give a written informed
consent.
Pre-treatment evaluation included physical examina-
tion, complete blood cell count and serum chemistry tests;
barium esophagram; upper gastro-esophageal endoscopy,
bronchoscopy (in upper and middle third tumors); endo-
scopic ultrasound (EUS); chest and abdominal helical CT
scan, and cervical ultrasound with Wne-needle aspiration
biopsy of suspicious nodes.
Patients were staged according to the results of the EUS
and CT scan. In the case of a discrepancy between the EUS
and CT scan Wndings, the patient was classiWed according
to the worst stage both for T and N.
Dysphagia was scored from 0 to 4 using a standard Wve
point scale [26].
The ethical committee of each participating center
approved both the protocol and informed consent.
Treatment
Chemotherapy
Three weekly induction doses of FLOX followed by Wve
doses with concurrent radiotherapy were delivered in an
outpatient setting through a central venous access.
BrieXy, oxaliplatin was administered as a 2-h infusion
on days 1, 8, 15, 29, 37, 43, 50, 57 at a dose of 60 mg/m2, as
previously established in our single-center phase I study, on
rectal cancer [4], and was followed by leucovorin 20 mg/m2
over 10 and a continuous infusion of Xuorouracil 200 mg/
m2 per day over days 1–22 and 29–64.
Patients received the planned treatment with no dose
reduction if they had a neutrophil count ¸ 1,500 l¡1 and a
platelet count ¸ 100,000 l¡1; otherwise chemotherapy
was delayed until complete toxicity recovery. Treatment
modiWcations were speciWed for hematological, gastrointes-
tinal and neurological toxicity using the NCI Common
Toxicity Criteria version 2.0.
Oxaliplatin and Xuorouracil were reduced to 75% of the
initial dose if any of the following events occurred: neutro-
phil count < 1,000 l¡1, platelet count < 50,000 l¡1, or
grades 3–4 non-hematological toxicity. In the case of neu-
trophil count < 500, fever or platelet count < 10,000 l¡1,
oxaliplatin and Xuorouracil doses were reduced to 60% of
the initial dose. The oxaliplatin dose alone was reduced to
75 or 60% of the initial dose in the case of grades 2 or 3
neurotoxicity, respectively, in the case of grade 4, the dose
was withheld.
Radiotherapy
Radiotherapy was delivered at 45 Gy in 25 fractions over
5 weeks, using a high-energy linear accelerator with a three-
dimensional multi-Weld technique, with a CT simulation,
from day 29 of chemotherapy treatment. The planned target
volume for carcinoma of the upper or middle third esopha-
gus included the primary tumor with 5 cm longitudinal mar-
gins, metastatic nodes with a 2 cm margin, supraclavicular
fossa and mediastinum. For carcinoma of the lower third
esophagus, the Weld was extended to include both the peri-
gastric and celiac nodes. This involved an initial phase using
anteroposterior/posteroanterior Welds to a dose of 30.6 Gy in
1.8 Gy fractions. The radiation portals were then changed to
encompass the primary tumor and metastatic nodes with a 2-
cm margin, using oV-cord conformal oblique Welds up to a
dose of 45 Gy. In patients with cervical esophageal tumor,
the radiotherapy dose was increased up to 60 Gy.
In the case of grade 3 or 4 mucositis or diarrhea, radio-
therapy was withdrawn till recovery.
Surgery
Patients were restaged 4–6 weeks after completion of
chemo-radiotherapy, repeating the pre-treatment staging
work-up. Medically Wt patients, whose tumors became radi-
cally resectable, were oVered an Ivor–Lewis esophagec-
tomy performed 6–8 weeks after chemo-radiation.
Resection of the esophagus and the proximal stomach was
performed through a separate right thoracic and middle
abdominal approach. Resection included excision of the
para-esophageal, intra-carenal, paracardial, left gastric, and
celiac lymph nodes (two-Weld lymphadenectomy). The
resected esophagus was usually replaced by the stomach
using a cervical or intra-thoracic esophagus–gastric anasto-
mosis, depending on the level of tumor location.
Assessment of response
Assessment of clinical response to protocol therapy was
performed 4 weeks after the end of hemo-radiotherapy
according to WHO criteria. In resected patients, a pCR was
deWned as the absence of viable tumor cells detected in the
primary tumor and the lymph nodes (pT0 pN0).
For patients who could not proceed to surgery, the clini-
cal CR was deWned as the absence of any residual tumor at
CT scan, endoscopy, EUS, biopsy, conWrmed by a new
endoscopy with biopsy and a PET-CT scan 3 months later.
Follow-up
Follow-up included a multidisciplinary visit every
3 months up to 2 years and every 6 months thereafter.123
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count, and chemistry panel; chest, abdomen and pelvic CT
and endoscopy with biopsy were performed every 6
months.
Statistical considerations
Using a single-stage design according to Fleming, a 25% 1-
year PFS or less was considered to be insuYcient to war-
rant further investigation. On the other hand, a probability
of PFS > 43% would be clinically suYcient and indicates
that further investigation of this regimen is appropriate.
This level of eYcacy was chosen according to our experi-
ence with 5FU/cisplatin/RT and considering the literature
data of eYcacy in patients with stage III and IVa LAEC.
With a sample size of 58 patients, the risk of erroneously
recommending a treatment whose PFS is inadequate
amounts to 5% while the chance of erroneously rejecting
the treatment is less than 15% in case of truly promising
activity set to 43% PFS.
All analyses were based on the intent-to-treat popula-
tion.
The PFS time was calculated from the beginning of che-
motherapy to the date of progressive disease, death or last
follow-up. The Kaplan–Meier method was used to estimate
the survival curve.
Actual dose intensity was calculated as recommended by
Hryniuk [22].
Analyses were performed using the SAS statistical pack-
age (SAS, release 9.1.3, Cary, NC, USA).
Results
A total of 59 patients were enrolled between November
2002 and June 2005. Patients’ characteristics are presented
in Table 1. Fifty-Wve patients (93%) had node metastases
(N1: 50, M1a: 5). All 59 enrolled patients were evaluated
for safety, PFS and OS. Figure 1 shows the progress of all
patients during the trial.
Compliance with the regimen and toxicity
Chemo-radiotherapy
Forty patients (68%) completed the eight planned FLOX
chemotherapy doses, without any modiWcations. The rea-
sons for not completing all chemotherapy were toxicity
(n = 17), progressive disease (n = 1) and refusal (n = 1).
The mean relative dose intensity of oxaliplatin and Xuoro-
uracil were 0.9 and 0.9 (induction phase) and 0.8 and 0.8
(concurrent phase), respectively (Fig. 2). Fifty-seven
patients started the concurrent phase of the treatment: 49
(83%) of them received the whole radiotherapy dose.
Unplanned interruptions of more than 2 days occurred in 14
patients as a result of toxicity; 8 patients discontinued
radiotherapy due to esophagitis and diarrhea after a median
of 40 Gy (range 22–40).
Table 2 lists the whole incidence of toxicity during
chemo-radiotherapy. Esophagitis was the most common
toxicity, with grade 3 or 4 in 15 patients (25%). Ten
patients (17%) suVered from grade 3 or 4 diarrhea. Hemato-
logical toxicity was modest with only four (7%) and two
(3%) patients with grade 4 neutropenia and thrombocytope-
nia, respectively. One patient had a pulmonary edema asso-
ciated with septicemia after the seventh week of treatment,
with complete resolution within 7 days. Another patient
had a candida pulmonary infection requiring a month of
intravenous anti-micotics. There was one possible treat-
ment-associated death: this patient who was diabetic died
of aspiration pneumonia while experiencing grade 4 neutro-
penia and trombocytopenia. Grade 3 neuropathy was
observed in three patients, Wve had a venous thrombosis
related to the central venous catheter, and seven patients
Table 1 Baseline characteristics
No. of patients %
Age, years

















Upper/mid thoracic 35 59





T4/M0 any N 10 16.9
Any T, any N, M1A 5 8.5123
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atin and lasting 24 h.
Esophagectomy and two-Weld lymphadenectomy was
performed on 33 patients (5 adenocarcinoma, 1 undiVeren-
tiated and 27 squamous cell) after a median interval of
6 weeks (range 3–13) from chemo-radiotherapy. Postopera-
tive complications of any grade occurred in 10 patients (one
adenocarcinoma, one undiVerentiated and eight squamous
cell; Table 3): of these, two (squamous cell) died of an
acute respiratory distress syndrome, one (undiVerentiated)
had septicemia related to a venous catheter gram-positive
infection.
EYcacy and surgical parameters
Patients’ outcome was assessed as of 1 September 2007.
The median follow-up time was 18.5 months (range 0.3–
54.7), and 39.7 months (range 26.4–54.7) for patients who
Fig. 1 Trial progress. CT chemotherapy, CRT chemo-radiotherapy
Fig. 2 Mean relative dose–intensities during each cycle of therapy.
Circles plot the dose–intensity with respect to the prescribed dose of
drug for each patient. Bars represent the mean relative dose–intensity.
Ox oxaliplatin, FU Xuorouracil
Table 2 Treatment induced toxicity
a Worst grade/patient, 59 patients
Toxicitya Grades 1–2 Grade 3 Grade 4
N % N % N %
Gastrointestinal
Esophagitis 9 15 12 20 3 5
Diarrhea 15 25 5 8 5 8
Nausea/vomiting 32 54 2 3 2 3
Blood/bone marrow
Leucopoenia 9 15 4 7 2 3
Neutropoenia 6 10 4 7
Thrombocytopoenia 8 14 2 3 2 3
Anemia 12 20 2 3
Cardiac toxicity 3 5 1 2
Asthenia 13 22 4 7
Neurology
Neuropathy 9 15 2 3
Numbness 22 37 1 2
Infection 2 3 1 2 2 3
Fever drug related 6 10 1 2
Renal 1 2 1 2
Dermatological 7 12 1 2
Hepatic 5 8
Table 3 Surgery outcomes
R0 Complete resection, R1 resection with microscopic residual dis-
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response (95% CI 46–72%) by radiological imaging, 12
had stable disease, 8 progressed and 4 died before evalua-
tion: two of a massive esophageal hemorrhage; one died
suddenly, at home 6 days after the third week of chemo-
therapy; and one died of aspiration pneumonia. Objective
responses were observed in 32 patients with squamous cell
histology, in 2 with adenocarcinoma and in the patient with
undiVerentiated cell histology.
Thirty-Wve patients (59%) underwent surgery. The rea-
sons for not undergoing surgical resection are listed in
Fig. 1. Table 3 summarizes surgical results. A complete
resection was achieved in 26 patients. A pCR (ypT0N0M0)
was documented in six (17% of resected) and three patients
had complete T clearance with only one node containing
tumor micro foci (ypT0N1M0). The pathological responses
were observed in seven patients with squamous cell histol-
ogy, in one with adenocarcinoma and the one with undiVer-
entiated cell histology.
Four patients with a complete tumor regression, docu-
mented by endoscopy, biopsy, CT and PET-CT scan, who did
not undergo resection, are still in complete clinical response
after a median follow-up of 40 months (range 36–48).
The median and 1-year PFS were 11 months (95% CI
6.5–14) and 47.5% (95% CI 34–59.5), respectively. Median
PFS for adenocarcinoma and squamous cell histology was
9 and 11 months, respectively.
The median OS was 18.5 months (95% CI 13–27),
12 months for adenocarcinoma and 19 for squamous cell
histology. The 1-year and 3-year OS probability was 63%
(95% CI 49–74) and 31.5% (95% CI 20–44), respectively
(Fig. 3).
In patients with clinical response, the median OS was
26.7 months (95% CI 18-) with 1-year and 3-year OS of
85.7% (95% CI 69–94) and 41.9% (95% CI 25–58), respec-
tively.
The median OS in the 33 resected patients was
29.3 months (95% CI 20-) with 1-year and 3-year OS of
81.8% (95% CI 64–91) and 40.9% (95% CI 24–57), respec-
tively. All patients with a pathological response were alive
at a median follow-up of 39 months except one patient with
ypT0N1M0 who died after 21 months from starting ther-
apy.
Site of the Wrst occurrence
Fifteen patients (25%) are still without recurrence at a
median follow-up of 40 months (range 26.4–54.7). The Wrst
site of recurrence was local in 12 (20%) and distant in 21
(36%).
Discussion
The treatment of patients with LAEC is challenging for
many reasons: the extension and localization of the tumor
at diagnosis, poor patients’ conditions and the frequent
presence of multiple co-morbidities, which hamper the full
administration of treatments and their eYcacy [36].
The activity of oxaliplatin, combined with FU or cis-
platin in diVerent schedules, with or without radiotherapy,
has been recently tested and reported in EC in diVerent
studies [25, 30–32].
Khushalani et al. [25] evaluated a standard dose of
85 mg/m2 every 2 weeks in a mixed population of stages II,
III, IVb EC, with a prevalence of adenocarcinomas (80%).
Mauer et al. [30] tested the same dose every 2 weeks, with-
out XRT in a phase I study on 35 patients with recurrent or
metastatic adeno and squamous esophageal cancer; O’Con-
nor et al. [32] studied this schedule in combination with RT
in 33 patients with adenocarcinoma and 9 with squamous
carcinoma. Maurel et al. [31] combined oxaliplatin with
cisplatin and 96-h FU infusion and Jatoi et al. [23] com-
bined oxaliplatin every 3 weeks with capecitabine, in
patients with metastatic esophageal adenocarcinoma and
gastric cardia. All the above-mentioned authors concluded
that oxaliplatin had signiWcant anti-tumor activity and a
favorable toxicity proWle in patients with esophageal
cancer.
Two phase III studies in advanced esophagogastric can-
cer have conWrmed the previous phase II Wndings establish-
ing that the oxaliplatin combinations were as eVective as
the cisplatin combinations and less toxic [2, 14].
Our study is the Wrst to evaluate a weekly combination of
oxaliplatin in previously untreated LAEC patients with a
high prevalence of squamous cell histology.
Squamous and adenocarcinoma of the esophagus are now
clearly recognized as diVerent entities, not only in epidemi-
ology, tumor location and postoperative complications, but
Fig. 3 Kaplan–Meier curves for progression-free survival (PFS) and
overall survival (OS)123
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due to secondary tumors and co-morbidities was reported in
squamous cell type and due to metastatic spreading in ade-
nocarcinoma [28, 35]. However, the low number of adeno-
carcinoma patients enrolled did not allow us to statically
compare the two histology populations.
Twenty-Wve percent of patients are alive without evi-
dence of recurrence at a median follow-up of 40 months.
Considering that we treated only patients who were not rad-
ically resectable at presentation; this demonstrates the
eYcacy of the oxaliplatin combination. The median OS of
18.5 months and 3-year OS of 31.5 months compare favor-
ably with the median OS of 12.5 months reported in the
RTOG–085 study [12, 21]. The activity observed compares
well also with the median OS of 17.7 months reported by
Bedenne et al. [6] and the 16.4 months reported by Stahl
et al. [37]. In our study, 87% of the patients had stage III
and 8% stage IVa disease; 17% had a T4 lesion. Moreover,
93% had nodal involvement which is the most important
prognostic factor [40]. In the RTOG-085 study, nodal
involvement was reported in only 13% of patients and there
were no patients with T4 or M1a disease. Stahl et al. [37]
study excluded patients with M1a disease and 18% of them
did not have evidence of nodal metastases; Bedenne et al.
[6] excluded patients with T4 and M1a lesions, and 59%
were without evidence of nodal metastases.
The activity observed with this oxaliplatin combination
is also better than that obtained in a similar patient popula-
tion using docetaxel in combination with cisplatin and FU,
followed by carboplatin and concurrent radiotherapy, and
surgery [10]. In advanced loco-regional disease, Polee et al.
[33] reported 17 of the 178 patients surviving at least
3 years using diVerent cisplatinum based combinations.
Adelstein et al. [1] obtained a median OS of 15 months and
a 3-year OS of 30% in T3–4 or N1 or M1 patients, using a
paclitaxel combination but reported a treatment related
mortality of 18%.
The overall pCR rate (17%) we obtained, even if appar-
ently lower than the average 24% calculated by Geh [19] in
a pooled analysis of 2,704 patients, is noteworthy consider-
ing that the possibility of achieving a pCR is related to the
stage [27], and that six patients with a clinical and long last-
ing CR did not undergo surgery. In the O’Connor [32]
study, the overall pCR rate was 25%; perhaps, the higher
dose of radiation used in this study (50.4 Gy) contributed to
increase the number of pCRs.
The radiotherapy dose is an important issue in the
achievement of loco-regional control. When radiotherapy is
employed as the sole therapeutic modality, there is an asso-
ciation between a higher dose and 5-year survival [41].
Instead, in the setting of concurrent CRT, the optimal radia-
tion dose has not been clearly deWned. Zhang et al. [41]
observed that in the correlation between the radiation dose,
concurrent with CT and loco-regional control, the slope of
the curve Xattened in the high-dose region, suggesting a
threshold in tumor response, and this Xattening became
quite evident after a dose of 45–46 Gy. Since higher doses
could increase treatment toxicity and surgical morbidity,
and esophagectomy was a planned option in our study, we
decided to limit the total dose to 45 Gy, although in the four
patients with tumor located in the cervical esophagus,
where an esophagectomy was not planned, we proceeded to
a total dose of 60 Gy without relevant toxicity.
In esophageal cancer, especially in patients with the
squamous cell histology type, co-morbidities often make
the delivery of treatment diYcult due to related toxicity.
In the RTOG randomized study, only 54% of patients
completed the four planned cycles of FU/cisplatin; side
eVects were severe in 44% and life-threatening in 20% and
10 patients (8.7%) died during the treatment [21]. Some
authors [8] reported up to 16% of treatment-related deaths
with the same combination, even using chemotherapy
alone. In a randomized study in operable patients [3], using
preoperative CT alone, we were able to deliver 68% of
three planned cycles of FU/cisplatin. In a similar study,
Kelsen et al. [24] delivered 71% of the planned CT preop-
eratively, and 38% postoperatively. In the present study,
despite the more advanced stage of disease, 68% of patients
completed the whole treatment plan, and 88% of the cycles
were administered without modiWcations.
The hematological toxicity of this combination was
moderate, grades 3–4 occurred in less than 10% of patients,
and this percentage is among the lowest reported in this set-
ting and not superior to that reported with oxaliplatin regi-
mens delivered without radiotherapy [2, 14].
Predominant toxicity was esophagitis and two-thirds of
the patients who had severe esophagitis also suVered from
diarrhea. The incidence of diarrhea was greater than that
observed in our phase I–II study in the preoperative treat-
ment of locally advanced rectal cancer [4]. We can argue
that the combination of malnourishment, smoke and alco-
hol abuse may make the intestinal mucosa more sensitive to
treatment damage, since gastrointestinal toxicity was more
frequent in patients with a greater weight loss. When we
became more aware of this risk and paid careful attention to
the Xuid and electrolytic balance, dehydration and related
life-threatening complications ceased. All the early and
toxic deaths occurred in patients with more advanced dis-
ease and squamous cell histology.
We proposed esophagectomy to all consenting patients
who were judged radically resectable after chemo-radio-
therapy to improve local control since a higher local failure
is reported in patients with a higher T staging [6, 18, 37].
We avoided esophagectomy in patients with cervical
involvement requiring a pharyngo-laryngectomy and in
poor condition patients where the risk of post-surgical123
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(6%) and the peri-operative complication (23%) rates were
similar to those reported with surgery alone [5, 39] and did
not seem to be increased by this preoperative treatment.
New protocols, combining oxaliplatin-containing regi-
mens with target agents such as cetuximab, which inhibits
the epidermal growth factor receptor (EGFR), and/or bev-
acizumab, which blocks the vascular endothelial growth
factor (VEGF), are in progress and could increase the
median survival and the still low rate of cure in EC. To this
aim, we have started a multi-center phase II study testing
the activity and safety of the addition of cetuximab to oxa-
liplatin/FU/leucovorin and radiotherapy in EC.
In conclusion, our results indicate that the oxaliplatin/
FU/leucovorin combination is active in the treatment of
EC. In view of the better toxicity proWle, the easier admin-
istration and the at least comparable activity, oxaliplatin
could safely replace cisplatin in the treatment of this tumor.
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